On July 3, Hanwha Life Insurance announced that it had obtained a nine-month exclusive use right from the Korea Life Insurance Association for a new rider designed to reduce the financial burden of treatment costs for cancer patients.


Hanwha Life Insurance Secures Exclusive Rights for Selective Benefit Major Cancer Treatment Rider View original image

The rider granted exclusive use rights is the "Selective Benefit Major Cancer Treatment Coverage S Rider II (once per year)." This rider has been included in both the "Hanwha Life Signature H Cancer Insurance" and the "Hanwha Life Signature H Integrated Insurance."


Selective benefits, for which further verification of effectiveness or cost-effectiveness is needed, are partially covered by the National Health Insurance, leaving patients to pay a high out-of-pocket rate ranging from 30% to as much as 90%. In addition, patients are not eligible for special calculation exemptions (which reduce out-of-pocket expenses for serious illnesses) or the out-of-pocket maximum system (which reimburses annual medical expenses exceeding a set limit), both of which are available for standard benefits.


Hanwha Life Insurance analyzed its proprietary insurance claim data alongside indemnity data to understand medical expense trends within the selective benefit range and included "Selective Benefit Major Cancer Treatment" as a coverage item. The company explained that customers can now combine coverage options based on their expected treatment cost burden, increasing premium efficiency while also reducing the inconvenience of having to add new riders whenever a new cancer treatment emerges.



Lee Sanghee, Head of Product Development at Hanwha Life Insurance, stated, "Although the selective benefit area is within the scope of the National Health Insurance, the high out-of-pocket expenses remain a significant burden for customers. Through data analysis, we identified coverage gaps hidden within the structure of existing cancer insurance and designed a product that directly addresses actual treatment costs. We will continue to develop coverage options that reflect the realities of treatment and changes in the healthcare environment going forward."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing